Search

Your search keyword '"Rouleau, Jean‐Lucien"' showing total 610 results

Search Constraints

Start Over You searched for: Author "Rouleau, Jean‐Lucien" Remove constraint Author: "Rouleau, Jean‐Lucien"
610 results on '"Rouleau, Jean‐Lucien"'

Search Results

1. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

3. Optimization of pharmacotherapies for ambulatory patients with heart failure and reduced ejection fraction is associated with improved outcomes

4. Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial

5. STICH3C: Rationale and Study Protocol

6. Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial

7. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial

8. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

10. Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists:insight from the PARADISE MI trial

11. A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol.

13. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

14. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

16. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

19. Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial

22. Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.

23. A disease-specific comorbidity index for predicting mortality in patients admitted to hospital with a cardiac condition

24. Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males

25. Growth Differentiation Factor-15 as a Predictor of Functional Capacity, Frailty, and Ventricular Dysfunction in Patients With Aortic Stenosis and Preserved Left Ventricular Ejection Fraction

26. sj-docx-1-aop-10.1177_10600280231179484 – Supplemental material for Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review

29. An association study ofABCG2rs2231142 on the concentrations of allopurinol and its metabolites

30. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF

31. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients with Acute Myocardial Infarction:Insights from the PARADISE-MI Trial

32. Global Variations in Heart Failure Etiology, Management, and Outcomes.

33. Pharmacogenomic markers of metoprolol and α-OH-metoprolol concentrations: a genome-wide association study

36. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

37. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction

38. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI):design and baseline characteristics

41. Relation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry)

43. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study

44. Coronary bypass surgery with or without surgical ventricular reconstruction

46. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.

47. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics

48. Rhythm control versus rate control for atrial fibrillation and heart failure

Catalog

Books, media, physical & digital resources